Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ACOR
- CUSIP: 00484M10
- Web: www.acorda.com
Capitalization:- Market Cap: $937.85 million
- Outstanding Shares: 46,758,000
Average Prices:- 50 Day Moving Avg: $18.37
- 200 Day Moving Avg: $20.23
- 52 Week Range: $13.60 - $33.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -56.53
- P/E Growth: 0.35
Sales & Book Value:- Annual Revenue: $523.08 million
- Price / Sales: 1.82
- Book Value: $14.46 per share
- Price / Book: 1.41
Profitability:- EBIDTA: $20.62 million
- Net Margins: -10.13%
- Return on Equity: -5.94%
- Return on Assets: -3.00%
Debt:- Debt-to-Equity Ratio: 0.48%
- Current Ratio: 2.08%
- Quick Ratio: 1.69%
Misc:- Average Volume: 875,300 shs.
- Beta: 1.64
- Short Ratio: 7.51
Frequently Asked Questions for Acorda Therapeutics (NASDAQ:ACOR)
What is Acorda Therapeutics' stock symbol?
Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."
How were Acorda Therapeutics' earnings last quarter?
Acorda Therapeutics, Inc. (NASDAQ:ACOR) issued its quarterly earnings results on Thursday, April, 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.08. The firm earned $119.39 million during the quarter, compared to the consensus estimate of $127.34 million. Acorda Therapeutics had a negative return on equity of 5.94% and a negative net margin of 10.13%. The company's revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the company posted $0.28 EPS. View Acorda Therapeutics' Earnings History.
When will Acorda Therapeutics make its next earnings announcement?
Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2017?
9 brokers have issued twelve-month price targets for Acorda Therapeutics' stock. Their predictions range from $19.00 to $35.00. On average, they expect Acorda Therapeutics' stock price to reach $24.67 in the next year. View Analyst Ratings for Acorda Therapeutics.
What are analysts saying about Acorda Therapeutics stock?
Here are some recent quotes from research analysts about Acorda Therapeutics stock:
- 1. According to Zacks Investment Research, "Acorda’s key multiple sclerosis drug Ampyra is facing several patent challenges. Recently a district court invalidated four patents of, Ampyra, thereby making way for generic versions of the drug. Sales Ampyra also declined sequentially in the quarter. The company’s share price underperformed the industry so far this year. With Ampyra facing patent issues, focus has shifted to the company’s late stage parkinson’s candidates Inbrija (formerly known as CVT-301) and tozadenant. However, the company recently submitted regulatory applications for Inbrija in the U.S. and plans to file for the same in the EU by the end of 2017. Meanwhile, Acorda is working on expanding its pipeline by entering into deals and pursuing acquisitions. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/19/2017)
- 2. Cowen and Company analysts commented, "ACOR released Q4 Ampyra revenue and provided 2017 Ampyra guidance, both just." (1/9/2017)
Who are some of Acorda Therapeutics' key competitors?
Some companies that are related to Acorda Therapeutics include Sarepta Therapeutics (SRPT), Radius Health (RDUS), Halozyme Therapeutics (HALO), Lexicon Pharmaceuticals (LXRX), NovoCure Limited (NVCR), Array BioPharma (ARRY), Dermira (DERM), Acceleron Pharma (XLRN), Amarin Corporation PLC (AMRN), Xencor (XNCR), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Synergy Pharmaceuticals (SGYP), Achaogen (AKAO), Aduro Biotech (ADRO), Omeros Corporation (OMER) and Ascendis Pharma A/S (ASND).
Who are Acorda Therapeutics' key executives?
Acorda Therapeutics' management team includes the folowing people:
- Ron Cohen M.D., President,Chief Executive Officer, Director
- David Lawrence, Chief Business Operations, Principal Accounting Officer
- Andrew R. Blight Ph.D., Chief Scientific Officer
- Jane Wasman J.D., President - International, General Counsel, Corporate Secretary
- Burkhard Blank M.D., Chief Medical Officer
- Andrew Hindman, Chief Business Development Officer
- Lauren M. Sabella, Chief Commercial Officer
- Catherine D. Strader, Director
- Barry E. Greene, Independent Director
- Peder K. Jensen M.D., Independent Director
Who owns Acorda Therapeutics stock?
Acorda Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Malaga Cove Capital LLC (0.12%), Whittier Trust Co. (0.08%), Louisiana State Employees Retirement System (0.04%), Aperio Group LLC (0.03%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Andrew Blight, David Lawrence, Enrique J Carrazana, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Michael W Rogers, Richard P Batycky, Ron Cohen and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.
Who bought Acorda Therapeutics stock? Who is buying Acorda Therapeutics stock?
Acorda Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Malaga Cove Capital LLC, State of Alaska Department of Revenue, Whittier Trust Co., Aperio Group LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for Acorda Therapeutics.
How do I buy Acorda Therapeutics stock?
Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acorda Therapeutics' stock price today?
One share of Acorda Therapeutics stock can currently be purchased for approximately $20.35.
MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Acorda Therapeutics (NASDAQ:ACOR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.33) |
| Consensus Price Target: | $24.67 (21.21% upside) |
Analysts' Ratings History for Acorda Therapeutics (NASDAQ:ACOR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/10/2017 | Jefferies Group LLC | Initiated Coverage | Hold -> Hold | $22.00 | Medium |  |
| 6/6/2017 | J P Morgan Chase & Co | Set Price Target | Hold | $24.00 | Low | |
| 6/7/2017 | Cowen and Company | Reiterated Rating | Outperform | $35.00 | Low | |
| 4/3/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral | $22.00 | High | |
| 4/3/2017 | Janney Montgomery Scott | Downgrade | Buy -> Neutral | $38.00 -> $19.00 | High | |
| 3/30/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $30.00 | High | |
| 2/15/2017 | Cantor Fitzgerald | Reiterated Rating | Neutral -> Positive | | N/A | |
| 1/8/2017 | Evercore ISI | Set Price Target | Hold | $23.00 | N/A | |
| 11/23/2016 | Leerink Swann | Reiterated Rating | Market Perform | | N/A | |
| 6/1/2016 | Aegis | Boost Price Target | Buy | $40.00 -> $52.00 | N/A | |
| 8/31/2015 | Raymond James Financial, Inc. | Initiated Coverage | Market Perform | | N/A | |
| 7/31/2015 | Canaccord Genuity | Reiterated Rating | Hold | $32.00 | N/A | |
(Data available from 7/20/2015 forward)
Earnings History for Acorda Therapeutics (NASDAQ:ACOR)Earnings History by Quarter for Acorda Therapeutics (NASDAQ ACOR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/26/2017 | | $0.49 | | | | | N/A | |
| 4/27/2017 | Q1 2017 | ($0.16) | ($0.08) | $127.34 million | $119.39 million | View | N/A | |
| 2/14/2017 | Q416 | ($0.18) | $0.05 | $137.90 million | $140.63 million | View | Listen | |
| 10/27/2016 | Q316 | ($0.26) | ($0.04) | $134.01 million | $135.61 million | View | Listen | |
| 7/28/2016 | Q216 | $0.18 | $0.07 | $128.33 million | $127.45 million | View | Listen | |
| 4/28/2016 | Q116 | $0.08 | $0.07 | $115.36 million | $115.90 million | View | Listen | |
| 2/11/2016 | Q415 | $0.22 | $0.28 | $128.24 million | $130.90 million | View | Listen | |
| 10/22/2015 | Q315 | $0.15 | $0.31 | $115.52 million | $148.20 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.01) | $0.31 | $110.84 million | $113.70 million | View | Listen | |
| 4/30/2015 | Q115 | $0.03 | ($0.02) | $100.20 million | $99.85 million | View | N/A | |
| 2/12/2015 | Q414 | $0.15 | $0.33 | $110.80 million | $117.90 million | View | N/A | |
| 10/30/2014 | Q314 | $0.04 | $0.34 | $94.70 million | $106.00 million | View | N/A | |
| 7/31/2014 | Q214 | $0.14 | $0.24 | $91.40 million | $97.13 million | View | N/A | |
| 5/6/2014 | Q114 | $0.04 | $0.08 | $81.30 million | $80.52 million | View | N/A | |
| 2/19/2014 | Q413 | $0.18 | $0.32 | $89.96 million | $92.59 million | View | N/A | |
| 10/31/2013 | Q313 | $0.13 | $0.36 | $90.01 million | $84.92 million | View | Listen | |
| 8/1/2013 | Q2 2013 | $0.09 | $0.25 | $82.57 million | $87.05 million | View | Listen | |
| 5/2/2013 | Q1 2013 | $0.20 | $0.09 | $80.77 million | $71.90 million | View | Listen | |
| 2/13/2013 | Q4 2012 | $0.15 | $0.24 | $78.90 million | $81.47 million | View | Listen | |
| 10/31/2012 | Q312 | $0.10 | $0.38 | $75.20 million | $77.44 million | View | N/A | |
| 7/31/2012 | | $0.27 | $0.27 | | | View | N/A | |
| 5/3/2012 | | $0.27 | $0.36 | | | View | N/A | |
| 2/16/2012 | | $0.24 | $0.40 | | | View | N/A | |
| 11/4/2011 | | $0.82 | $0.47 | | | View | N/A | |
| 8/1/2011 | | $0.10 | $0.01 | | | View | N/A | |
| 5/5/2011 | | $0.17 | ($0.02) | | | View | N/A | |
| 2/17/2011 | | $0.17 | $0.09 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Acorda Therapeutics (NASDAQ:ACOR)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 2 | ($0.03) | $0.26 | $0.12 |
| Q3 2017 | 2 | $0.21 | $0.56 | $0.39 |
| Q4 2017 | 2 | $0.32 | $0.76 | $0.54 |
(Data provided by Zacks Investment Research)
Dividend History for Acorda Therapeutics (NASDAQ:ACOR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Acorda Therapeutics (NASDAQ:ACOR)Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/16/2017 | Ron Cohen | Insider | Buy | 20,000 | $16.95 | $339,000.00 | |
| 5/15/2017 | Andrew A Hindman | Insider | Sell | 7,704 | $15.75 | $121,338.00 | |
| 12/14/2016 | Ron Cohen | Insider | Sell | 40,172 | $20.75 | $833,569.00 | |
| 10/21/2016 | Richard P Batycky | Insider | Sell | 2,063 | $20.30 | $41,878.90 | |
| 10/7/2016 | David Lawrence | Insider | Sell | 250 | $20.82 | $5,205.00 | |
| 10/3/2016 | Jane Wasman | Insider | Sell | 3,750 | $20.78 | $77,925.00 | |
| 9/23/2016 | Jane Wasman | Insider | Sell | 500 | $27.32 | $13,660.00 | |
| 6/22/2016 | David Lawrence | Insider | Sell | 500 | $25.09 | $12,545.00 | |
| 6/8/2016 | Steven M Rauscher | Director | Sell | 1,086 | $27.83 | $30,223.38 | |
| 5/13/2016 | Andrew A Hindman | Insider | Sell | 4,860 | $26.11 | $126,894.60 | |
| 4/19/2016 | Lorin Randall | Director | Sell | 1,488 | $28.68 | $42,675.84 | |
| 1/4/2016 | Ian F. Smith | Director | Sell | 13,231 | $41.85 | $553,717.35 | |
| 12/23/2015 | Jane Wasman | insider | Sell | 10,751 | $43.10 | $463,368.10 | |
| 12/22/2015 | Lauren M. Sabella | insider | Sell | 7,113 | $42.04 | $299,030.52 | |
| 12/21/2015 | Jane Wasman | Insider | Sell | 817 | $42.00 | $34,314.00 | |
| 12/18/2015 | David Lawrence | insider | Sell | 39,026 | $40.63 | $1,585,626.38 | |
| 12/17/2015 | Lauren M. Sabella | insider | Sell | 14,229 | $40.00 | $569,160.00 | |
| 12/1/2015 | Enrique J Carrazana | Insider | Sell | 7,218 | $38.08 | $274,861.44 | |
| 12/1/2015 | Ron Cohen | CEO | Sell | 11,850 | $38.08 | $451,248.00 | |
| 10/19/2015 | Andrew Blight | insider | Sell | 32,500 | $30.87 | $1,003,275.00 | |
| 10/7/2015 | Michael W. Rogers | CFO | Sell | 5,700 | $30.24 | $172,368.00 | |
| 10/5/2015 | Jane Wasman | insider | Sell | 3,750 | $31.75 | $119,062.50 | |
| 10/5/2015 | Ron Cohen | CEO | Sell | 135,000 | $28.03 | $3,784,050.00 | |
| 9/21/2015 | Andrew Blight | insider | Sell | 13,085 | $31.30 | $409,560.50 | |
| 5/15/2015 | Andrew A Hindman | Insider | Sell | 4,779 | $29.82 | $142,509.78 | |
| 1/12/2015 | Enrique J Carrazana | Insider | Sell | 97,993 | $42.21 | $4,136,284.53 | |
| 12/18/2014 | David Lawrence | Insider | Sell | 27,109 | $40.11 | $1,087,341.99 | |
| 12/18/2014 | John P Kelley | Director | Sell | 10,000 | $40.00 | $400,000.00 | |
| 12/1/2014 | David Lawrence | Insider | Sell | 8,898 | $35.60 | $316,768.80 | |
| 12/1/2014 | Lauren M Sabella | VP | Sell | 3,242 | $35.58 | $115,350.36 | |
| 12/1/2014 | Michael W Rogers | CFO | Sell | 230 | $35.58 | $8,183.40 | |
| 12/1/2014 | Ron Cohen | CEO | Sell | 34,394 | $35.59 | $1,224,082.46 | |
| 10/7/2014 | Michael W Rogers | CFO | Sell | 5,700 | $33.10 | $188,670.00 | |
| 10/3/2014 | Jane Wasman | Insider | Sell | 3,750 | $34.13 | $127,987.50 | |
| 9/24/2014 | Jane Wasman | Insider | Sell | 14,923 | $36.00 | $537,228.00 | |
| 8/27/2014 | Jane Wasman | Insider | Sell | 14,923 | $33.00 | $492,459.00 | |
| 12/5/2013 | Lauren Sabella | VP | Sell | 8,797 | $31.81 | $279,832.57 | |
| 12/2/2013 | Enrique Carrazana | Insider | Sell | 1,640 | $33.56 | $55,038.40 | |
| 10/15/2013 | Enrique J Carrazana | Insider | Sell | 3,333 | $32.38 | $107,922.54 | |
| 10/3/2013 | Jane Wasman | Insider | Sell | 3,750 | $35.74 | $134,025.00 | |
| 8/20/2013 | Ron Cohen | CEO | Sell | 149,000 | $34.10 | $5,080,900.00 | |
| 8/2/2013 | John Kelley | Director | Sell | 15,000 | $38.00 | $570,000.00 | |
| 7/19/2013 | Andrew Blight | Insider | Sell | 19,296 | $37.82 | $729,774.72 | |
| 6/10/2013 | Ron Cohen | CEO | Sell | 11,000 | $34.15 | $375,650.00 | |
| 5/8/2013 | Sandra Phd Panem | Director | Sell | 10,000 | $33.80 | $338,000.00 | |
| 12/4/2012 | Lauren M Sabella | VP | Sell | 4,364 | $24.58 | $107,267.12 | |
| 12/3/2012 | Andrew Blight | Insider | Sell | 7,200 | $24.20 | $174,240.00 | |
| 12/3/2012 | David Lawrence | CFO | Sell | 9,313 | $24.21 | $225,467.73 | |
| 12/3/2012 | Ron Cohen | CEO | Sell | 16,407 | $24.22 | $397,377.54 | |
| 11/13/2012 | Sandra Phd Panem | Director | Sell | 22,569 | $24.12 | $544,364.28 | |
(Data available from 1/1/2013 forward)
Headline Trends for Acorda Therapeutics (NASDAQ:ACOR)
Latest Headlines for Acorda Therapeutics (NASDAQ:ACOR)
| Source: |
|
| Date | Headline |
|---|
 | Acorda Therapeutics, Inc. (ACOR) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 19 at 8:15 AM |
 | Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled for July 27, 2017 - Business Wire (press release)
www.businesswire.com - July 13 at 8:55 PM |
 | Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled for July 27, 2017
finance.yahoo.com - July 13 at 3:51 PM |
| ETFs with exposure to Acorda Therapeutics, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 3:51 PM |
| Acorda Therapeutics, Inc. (NASDAQ:ACOR) Expected to Post Q2 2017 Earnings of $0.26 Per Share
www.americanbankingnews.com - July 13 at 9:34 AM |
 | Acorda's Pipeline Has Potential - Seeking Alpha
seekingalpha.com - July 12 at 3:48 PM |
| Jefferies Group LLC Begins Coverage on Acorda Therapeutics, Inc. (NASDAQ:ACOR)
www.americanbankingnews.com - July 10 at 5:26 PM |
 | Global Pain Drug Development Pipeline Review Report 2017 Featuring 170+ Leading Pharma Companies
www.bizjournals.com - July 10 at 3:29 PM |
 | BRIEF-Christopher James reports 5.9 pct passive stake in Acorda Therapeutics ...
www.reuters.com - July 8 at 8:15 AM |
| Acorda Therapeutics Inc (ACOR) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - July 7 at 5:06 PM |
| Acorda Therapeutics, Inc. (NASDAQ:ACOR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 4 at 5:20 PM |
| Multiple Sclerosis Drugs and Therapeutic Pipeline Review H1 2017 Research Available at RnR Market Research
www.bizjournals.com - July 4 at 4:29 PM |
 | Acorda Files NDA for Parkinson's Disease Candidate Inbrija - Nasdaq
www.nasdaq.com - June 30 at 3:34 PM |
| Acorda Files NDA for Parkinson's Disease Candidate Inbrija
finance.yahoo.com - June 30 at 3:34 PM |
| Acorda Therapeutics, Inc. (ACOR) Expected to Post Quarterly Sales of $139.89 Million
www.americanbankingnews.com - June 30 at 2:06 PM |
 | Acorda Therapeutics (ACOR) Submits NDA for INBRIJATM - StreetInsider.com
www.streetinsider.com - June 30 at 1:44 AM |
| Acorda Therapeutics (ACOR) Submits NDA for INBRIJATM
www.streetinsider.com - June 29 at 8:42 PM |
| BRIEF-Acorda submits new drug application to U.S. Food And Drug Administration
www.reuters.com - June 29 at 8:42 PM |
| Acorda Submits New Drug Application to U.S. Food and Drug Administration for INBRIJATM (CVT-301, Levodopa Inhalation Powder)
finance.yahoo.com - June 29 at 8:42 PM |
| Zacks: Brokerages Expect Acorda Therapeutics, Inc. (ACOR) to Post $0.12 EPS
www.americanbankingnews.com - June 28 at 12:26 PM |
| ETFs with exposure to Acorda Therapeutics, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 3:44 PM |
| Biotech Insider Just Loaded Up $234 Million Worth the Stock
finance.yahoo.com - June 21 at 3:40 PM |
| Ron Cohen Buys 20,000 Shares of Acorda Therapeutics, Inc. (ACOR) Stock
www.americanbankingnews.com - June 20 at 4:22 PM |
| Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe
finance.yahoo.com - June 16 at 3:41 PM |
| ETFs with exposure to Acorda Therapeutics, Inc. : June 15, 2017
finance.yahoo.com - June 15 at 3:35 PM |
| Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 3:17 PM |
| Acorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : June 12, 2017
finance.yahoo.com - June 12 at 3:44 PM |
| BRIEF-Acorda Therapeutics, in May 2017, filed planned appeal of decision on 4 invalidated patents with U.S. court of appeals for federal circuit
www.reuters.com - June 10 at 3:19 PM |
| Acorda Therapeutics Inc (ACOR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - June 9 at 7:02 PM |
| Zacks Initiates on Pulmatrix (NASDAQ:PULM)
finance.yahoo.com - June 9 at 3:23 PM |
| Acorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACOR-US : June 9, 2017
finance.yahoo.com - June 9 at 3:23 PM |
| Acorda Therapeutics Inc (ACOR) Given a $24.00 Price Target at JPMorgan Chase & Co.
www.americanbankingnews.com - June 7 at 6:40 PM |
| Acorda Therapeutics Inc (ACOR) Receives "Outperform" Rating from Cowen and Company
www.americanbankingnews.com - June 7 at 10:26 AM |
 | Acorda stock surges 10% on positive late-stage Parkinson's results - MarketWatch
www.marketwatch.com - June 7 at 1:30 AM |
| BRIEF-Acorda Therapeutics says expects results from Tozadenant phase 3 clinical trial in Q1 2018
www.reuters.com - June 6 at 8:28 PM |
| Acorda Therapeutics (ACOR) Presents Parkinson's Disease Drug Overview - Slideshow
seekingalpha.com - June 6 at 8:28 PM |
| Acorda Presenting New Tozadenant Data at 2017 MDS Congress
finance.yahoo.com - June 6 at 8:28 PM |
| Acorda Therapeutics Inc (ACOR): Key Takeaways from CVT-301 Presentation at MDS
finance.yahoo.com - June 6 at 8:28 PM |
| BRIEF-Acorda Therapeutics says expects results from Tozadenant phase 3 clinical trial in Q1 2018 - Reuters
www.reuters.com - June 6 at 3:26 PM |
| Acorda Presenting New Tozadenant Data at 2017 MDS Congress ... - Business Wire (press release)
www.businesswire.com - June 6 at 3:26 PM |
| Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms
finance.yahoo.com - June 6 at 10:16 AM |
| Acorda stock surges 10% on positive late-stage Parkinson's results
finance.yahoo.com - June 6 at 10:16 AM |
 | Acorda Therapeutics Inc. (ACOR) Is Climbing On Phase 3 Study Results
www.rttnews.com - June 5 at 11:46 PM |
| Acorda Therapeutics +8.5% on positive results in Parkinson's disease drug - Seeking Alpha
seekingalpha.com - June 5 at 6:40 PM |
| CVT-301 Phase 3 Data Showed Significantly Improved Motor Function During OFF Periods in Parkinson’s Disease
finance.yahoo.com - June 5 at 6:40 PM |
| $139.89 Million in Sales Expected for Acorda Therapeutics Inc (ACOR) This Quarter
www.americanbankingnews.com - June 4 at 9:06 AM |
| Form 4 ACORDA THERAPEUTICS INC For: May 31 Filed by: Jensen Peder
www.streetinsider.com - June 3 at 1:58 AM |
| $0.12 EPS Expected for Acorda Therapeutics Inc (ACOR) This Quarter
www.americanbankingnews.com - June 2 at 10:14 AM |
| Form 8-K ACORDA THERAPEUTICS INC For: May 31 - StreetInsider.com
www.streetinsider.com - June 1 at 3:26 PM |
| Why Is Acorda (ACOR) Down 8.4% Since the Last Earnings Report?
finance.yahoo.com - June 1 at 3:26 PM |
Acorda Therapeutics (ACOR) Chart for Thursday, July, 20, 2017
